Bringing Hope
to People Living with Neurodegenerative Diseases

Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update

Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer’s Disease